Serial							No. 10466/18	3				
Senal No. Filing Date 09/839,684 April 19, 2001 Inventor(s)			To be assigned					Art Unit	Pr-			
Frankl	in Okumu Invention									, CA		
SUST	NED RELEASE	FORMULAT	IONS							WA 2 A		
າດທາ ໄ			TO THE C	OMMISSIONI	ER FOR	R PATENTS			10	125 700		
2007	Transmitted he	erewith is a	Sunniemental Info				m DTO 1	440: 4		17>0		
Interna										90		
A STATE OF THE STA	Small entity st submitted.	atus of this	application unde	er 37 CFR §	1.27 h	as been esta	ablished b	y verifi	ed statement	previously		
										<i>₽</i> ∧		
	A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.											
	Petition for amonth extension of time.											
	A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed. Petition for amonth extension of time. No additional fee is required. The fee has been calculated as shown below: Claims Remaining Previously Previously Previously Previously or Previously Small Entity											
	The fee has bee	en calculated	d as shown below:							189 Jan		
						Small	Entity		Other	Than		
	Claims Remaining		Highest No.	_				or	Sman	Entity		
	After Amendment	0-	Previously Paid For	Present Extra		Rate	Add'l Fee		Rate	Add'I Fee		
Total	, unenament	Minus		 	-			_	<u> </u>	1.00		
ndep.		Minus Minus		+		x \$9=		4	x \$18=			
First Pre	sentation of Multip		 m	-	-	x 42=		\dashv	x \$84=			
-						+\$140= Total	\$	\dashv	+ \$280=			
						add'I fee		_	Total add'l fee	\$		
	Please charge Decopy of this sheet	eposit Acco t is enclosed	unt No. 23-1925 (E J.	BRINKS HOF	ER GIL	SON & LIONE	E) in the ar	nount c	of \$ A	duplicate		
	A check in the amount of \$ to cover the filing fee is enclosed.											
\boxtimes						1.00						
	any patent appli	cation proc	authorized to char essing fees unde unt No. 23-1925	er 37 CFR §	1.17	associated w	fees requi ith this c	red und ommun	ler 37 CFR § ication or cr	1.16 and edit anv		
\triangleleft				dapiloate et	py of the	iis stieet is en	iciosea.					
	I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate											
	or and sneet	is circlosed	•									
				Respectful	ly subm	nitted,						
				- Pris	<u> </u>	M						
				Jonathan P Registration		8,338				-		
RINKS H O. BOX	OFER GILSON &	LIONE		Agent for A	pplican	t						
11CAGO 12) 321~	, ILLINOIS 60610											
121 3214	4200											

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an elope, with sufficient postage, addressed to: Commissioner for Patents, Washington, D.C. 20231, on

March 13, 2002

Date of Deposit

Jonathan P. Taylor

Name of Applicant, Assignee or Registered Representative

Signature

3/13/02

TECH CENTER 1600/2900

MAR 2 5 7002

TC 1700

Our Case No.: 10466/18

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: To be assigned

Group Art Unit No.: 1615

In re Application of:

Franklin Okumu

Serial No.: 09/839,684

Filing Date: April 19, 2001

For:

SUSTAINED RELEASE

FORMULATIONS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed below and on the attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

The references now cited are the following:

FOREIGN PATENT APPLICATIONS

DOCUMENT NUMBER	DATE	COUNTRY
0 216 485	4/1/1987	Europe
WO 92/17200	10/15/1992	PCT
WO 00/78335	12/28/2000	PCT

OTHER ART

1. Smith et al., "A Novel Parenteral Delivery System", *Pharmaceutical Research*, XP-001041946, pg. 300

In accordance with 37 C.F.R. § 1.97(g),(h), this Supplemental Information

Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Supplemental Information Disclosure Statement is being filed prior to the receipt of the first Official Action reflecting an examination on the merits and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these material, the Commissioner is hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925. A duplicate copy of this document is enclosed.

In accordance with 37 C.F.R. § 1.97(e)(1), Applicant(s) hereby certify that each item of the information disclosed in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to filing of the present statement, as evidenced by the date of the enclosed search report.

Applicant(s) respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

Johathan P. Taylor

Registration No. 48,338 Agent for Applicant(s)

BRINKS HOFER GILSON & LIONE P.O. Box 10395 Chicago, IL 60610 (312) 321-4200